Inogen - INGN Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" INGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INGN, but not buy additional shares or sell existing shares.
View INGN analyst ratings or view top-rated stocks.

4 brokerages have issued 12 month price objectives for Inogen's shares. Their INGN share price forecasts range from $30.00 to $47.00. On average, they anticipate the company's stock price to reach $41.00 in the next year. This suggests a possible upside of 64.9% from the stock's current price.
View analysts price targets for INGN or view top-rated stocks among Wall Street analysts.

Inogen's stock was trading at $34.00 at the beginning of the year. Since then, INGN stock has decreased by 26.9% and is now trading at $24.86.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our INGN earnings forecast.

Inogen, Inc. (NASDAQ:INGN) announced its quarterly earnings data on Thursday, August, 4th. The medical technology company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.40) by $0.38. The medical technology company had revenue of $103.38 million for the quarter, compared to analysts' expectations of $100.64 million. Inogen had a negative net margin of 8.03% and a negative trailing twelve-month return on equity of 5.35%. The company's revenue for the quarter was up 1.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.22 EPS.

Inogen issued an update on its third quarter 2022 earnings guidance on Thursday, September, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $97.00 million-$100.00 million, compared to the consensus revenue estimate of $98.77 million.

70 employees have rated Inogen Chief Executive Officer Scott Wilkinson on Glassdoor.com. Scott Wilkinson has an approval rating of 46% among the company's employees. This puts Scott Wilkinson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), (MDVN) (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), First Solar (FSLR), Intel (INTC) and Netflix (NFLX).

Inogen trades on the NASDAQ under the ticker symbol "INGN."

Shares of INGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INGN stock can currently be purchased for approximately $24.86.

Inogen (NASDAQ:INGN) has a market capitalization of $568.55 million and generates $358 million in revenue each year. The medical technology company earns $-6,330,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis.

The company employs 1,021 workers across the globe.

Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The official website for the company is www.inogen.com. The medical technology company can be reached via phone at (805) 562-0500 or via email at mpigeon@inogen.net.